Vivesto (VIVE) Stock Overview

Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. More details

VIVE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VIVE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Vivesto AB Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vivesto
Historical stock prices
Current Share PriceSEK 0.23
52 Week HighSEK 0.37
52 Week LowSEK 0.20
Beta1.08
1 Month Change0.87%
3 Month Change2.21%
1 Year Change-13.94%
3 Year Change-66.79%
5 Year Change-95.55%
Change since IPO-99.11%

Recent News & Updates

Recent updates

Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Apr 25
Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Aug 21
Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Shareholder Returns

VIVESE BiotechsSE Market
7D-0.2%-1.5%-0.7%
1Y-13.9%-11.4%-3.0%

Return vs Industry: VIVE underperformed the Swedish Biotechs industry which returned -11.4% over the past year.

Return vs Market: VIVE underperformed the Swedish Market which returned -3% over the past year.

Price Volatility

Is VIVE's price volatile compared to industry and market?
VIVE volatility
VIVE Average Weekly Movement3.4%
Biotechs Industry Average Movement10.4%
Market Average Movement6.3%
10% most volatile stocks in SE Market13.8%
10% least volatile stocks in SE Market3.3%

Stable Share Price: VIVE has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: VIVE's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19884Erik Kinnmanwww.vivesto.com

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.

Vivesto AB Fundamentals Summary

How do Vivesto's earnings and revenue compare to its market cap?
VIVE fundamental statistics
Market capSEK 124.56m
Earnings (TTM)-SEK 39.62m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.1x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIVE income statement (TTM)
RevenueSEK 0
Cost of RevenueSEK 0
Gross ProfitSEK 0
Other ExpensesSEK 39.62m
Earnings-SEK 39.62m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 12, 2025

Earnings per share (EPS)-0.074
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VIVE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/20 15:53
End of Day Share Price 2025/07/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vivesto AB is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Camilla OxhamreCarnegie Investment Bank AB
Klas PalinDNB Carnegie Commissioned Research
Susie JanaEdison Investment Research